Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Motzer

Showing results (71-80 of 436) with videos related to

Pageof 44
Sort By:
The Oncologist|October 8, 2008
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategiesThomas E Hutson, Robert A Figlin, John G Kuhn, et al.
The Journal of Urology|July 19, 2008
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinomaScott E Eggener, Ofer Yossepowitch, Shilajit Kundu, et al.
British Journal of Cancer|March 27, 2018
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinomaRobert J Motzer, Bernard Escudier, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaRobert J Motzer, Jennifer Bacik, Barbara A Murphy, et al.
Journal of the National Cancer Institute|June 15, 2007
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinibDarren R Feldman, Andrew J Martorella, Richard J Robbins, et al.
The Lancet. Oncology|January 14, 2016
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Thomas E Hutson, Min Ren, et al.
European Urology Open Science|September 1, 2021
Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell CarcinomaChung-Han Lee, Yin Wan, Alan Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histologyRobert J Motzer, Jennifer Bacik, Tania Mariani, et al.
The New England Journal of Medicine|May 3, 2014
Overall survival in renal-cell carcinoma with pazopanib versus sunitinibRobert J Motzer, Thomas E Hutson, Lauren McCann, et al.
BMC Cancer|February 19, 2018
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysisLin Yang, Anna Alyasova, Dingwei Ye, et al.
Pageof 44

Showing results (71-80 of 436) with videos related to

Sort By:
Pageof 44
The Oncologist|October 8, 2008
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategiesThomas E Hutson, Robert A Figlin, John G Kuhn, et al.
The Journal of Urology|July 19, 2008
Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinomaScott E Eggener, Ofer Yossepowitch, Shilajit Kundu, et al.
British Journal of Cancer|March 27, 2018
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinomaRobert J Motzer, Bernard Escudier, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaRobert J Motzer, Jennifer Bacik, Barbara A Murphy, et al.
Journal of the National Cancer Institute|June 15, 2007
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinibDarren R Feldman, Andrew J Martorella, Richard J Robbins, et al.
The Lancet. Oncology|January 14, 2016
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinomaRobert J Motzer, Thomas E Hutson, Min Ren, et al.
European Urology Open Science|September 1, 2021
Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell CarcinomaChung-Han Lee, Yin Wan, Alan Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histologyRobert J Motzer, Jennifer Bacik, Tania Mariani, et al.
The New England Journal of Medicine|May 3, 2014
Overall survival in renal-cell carcinoma with pazopanib versus sunitinibRobert J Motzer, Thomas E Hutson, Lauren McCann, et al.
BMC Cancer|February 19, 2018
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysisLin Yang, Anna Alyasova, Dingwei Ye, et al.
Pageof 44